Healthcare Industry News: Allergan
News Release - March 16, 2006
Rob Bancroft Named Senior Vice President, Sales and Marketing, HEALTHPOINT Tissue ManagementFORT WORTH, Texas, March 16 (HSMN NewsFeed) -- Michael E. Steadman, President of Tissue Management for HEALTHPOINT®, Ltd., a DFB Pharmaceuticals, Inc. affiliate company, has announced that Rob Bancroft has been appointed to the position of Senior Vice President, Sales and Marketing for HEALTHPOINT's Tissue Management Division. Mr. Bancroft was most recently Vice President of Marketing, Tissue Management, a position he has held since joining HEALTHPOINT in November of 2004.
In Mr. Bancroft's newly expanded role, he will assume responsibility for the sales department and the business intelligence and operations department.
Current marketing focus at HEALTHPOINT Tissue Management is on incontinence related skin problems; chronic wounds such as pressure, venous, and diabetic ulcers, and associated skin conditions like peri-wound dermatitis and maceration; and on unique therapies for burns.
HEALTHPOINT, founded in 1992, is a specialty pharmaceutical company focusing on the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices worldwide. Its Tissue Management business includes marketing prescription drugs and innovative prescription technologies and devices for skin and soft tissue, including the treatment of acute and chronic tissue compromises and full and partial thickness wounds, and for the management of intact skin.
"In his tenure at HEALTHPOINT, Rob has been instrumental in championing the strategic vision for Tissue Management marketing," commented Mr. Steadman. "Through his leadership, he has accomplished our goal of positioning us uniquely within our industry. I am proud of the progress and contributions that Rob has made and know that with his guidance, we will achieve a successful integration of sales and marketing."
"Knowing that I contribute to the realization of HEALTHPOINT's vision -- to develop differentiated pharmaceutical and biological technologies to address the very substantial unmet needs in wound care -- is extremely satisfying to me," said Mr. Bancroft. "I am honored that through my new role, I can help bring HEALTHPOINT ever closer to that vision."
Prior to joining HEALTHPOINT, Mr. Bancroft was senior marketing director for Global BOTOX® at Allergan, Inc. BOTOX has been one of the most successful therapeutics worldwide, a franchise that exceeds $800 million annually.
"Rob's in-depth background and experience in pharmaceutical and biologic development and marketing has enriched HEALTHPOINT's commitment to pharmaceuticals and biologics for wound care," said Mr. Steadman. "He had enormous success at Allergan due to his strategic vision and leadership. At HEALTHPOINT, these two vital characteristics have been critical to achieving our excellent growth plans and strengthening our commitment to succession planning."
Mr. Bancroft began his career in sales of topical ophthalmics for Allergan's U.S. Eye Care business in the late 1980s before rising to senior director of global marketing.
A 1987 graduate of Indiana University in Bloomington with a Bachelor of Science degree in biology, Mr. Bancroft completed his Master of Business Administration in marketing and finance in 1996 at the University of Southern California, Los Angeles.
Since its inception in 1992, HEALTHPOINT has established a U.S. presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices for tissue management, dermatology, and surgical indications. An aggressive research and development effort has brought HEALTHPOINT's unique technologies to the market, setting the pace for its highly trained field sales organization of direct sales representatives. HEALTHPOINT, with over 300 employees, is a DFB Pharmaceuticals, Inc. affiliate company. HEALTHPOINT is based in Fort Worth, Texas. Visit HEALTHPOINT's web site at http://www.healthpoint.com .
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.